Podcast

Howard "Skip" Burris, MD: A Passion for Befriending Patients and Always Being Kind

Howard A. Burris, MD, also known as "Skip," of Sarah Cannon Research Institute, discussed how he wound up in the oncology space, his passion for getting to know and helping his patients, and some proud moments throughout his monumental career.

We had the pleasure of sitting down with Howard A. Burris, MD, also known as Skip, is the president of clinical operations and chief medical officer of Sarah Cannon Research Institute, as well as an associate of Tennessee Oncology. Not only is he a 2014 Giant of Cancer Care® in Drug Development, Dr Burris is also the elected president of ASCO for 2019 to 2020.

He has led a number of research endeavors and has been a part of the development of several agents now available for breast cancer treatment, such as ado-trastuzumab emtansine, everolimus, and gemcitabine.

In our exclusive interview, Dr. Burris spent time discussing how he wound up in the oncology space, his passion for getting to know and helping his patients, and some of his proudest moments throughout his monumental career, which includes his time as president of ASCO.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

May 15th 2025 - May 16th 2026

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer
Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

May 15th 2025 - May 16th 2026

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

May 14th 2025 - Jun 19th 2025

online-activity